Equity Overview
Price & Market Data
Price: $25.39
Daily Change: -$0.08 / 0.32%
Range: $24.29 - $26.79
Market Cap: $279,764,800
Volume: 65,990
Performance Metrics
1 Week: 4.23%
1 Month: -9.09%
3 Months: 103.3%
6 Months: 54.60%
1 Year: 111.6%
YTD: 111.6%
Company Details
Employees: 50
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.